I-AASraw ivelisa i-NMN kunye ne-NRC powders ngobuninzi!

Afatinib

Akukho kalo Udidi:

I-Afatinib powder, ithengiswa phantsi kwegama legama elithi Gilotrif phakathi kwabanye, iyeza elisetyenziselwa ukunyanga i-cell carcinoma (NSCLC) engeyiyo encinci ye-tyrosine kinase inhibitor yosapho lwamayeza.Yathathwa ngomlomo.

Ingcaciso yeMveliso

Iimpawu ezisisiseko

Igama lemveliso Umgubo weAfatinib
Inani leCAS 439081-18-2
I-Molecular Formula Ikhowudi yemali ye-C24H25ClFN5O3
Ubukhulu beFormula 485.9
Iintetho ezifanayo Umgubo weAfatinib;

439081-18-2;

850140-72-6;

IBHAYIBHILE2992;

Tovok.

Kubonakala Powstalline powder
Ukugcina nokuPhatha Yigcine kubushushu begumbi kwaye kude nobushushu obuninzi kunye nokufuma.

 

Inkcazo yePowderib Powder

I-Afatinib powder, ithengiswa phantsi kwegama legama elithi Gilotrif phakathi kwabanye, iyeza elisetyenziselwa ukunyanga i-cell carcinoma (NSCLC) engeyiyo encinci ye-tyrosine kinase inhibitor yosapho lwamayeza.Yathathwa ngomlomo.

I-Afatinib powder isetyenziselwa ikakhulu ukunyanga iimeko ze-NSCLC ezigcina utshintsho kwi-epidermal growth factor receptor (EGFR) gene.

 

Indlela ye-Afatinib Powder yokuSebenza

Njenge-lapatinib kunye ne-neratinib, i-afatinib powder yiprotein kinase inhibitor ekwagcina kungathinteleki ukuthintela ukukhula kwe-epidermal factor receptor 2 (Her2) kunye ne-epidermal growth factor receptor (EGFR) kinases. I-Afatinib powder ayisebenzi kuphela ngokuchasene notshintsho lwe-EGFR olujolise kwisizukulwane sokuqala se-tyrosine-kinase inhibitors (TKIs) njenge-erlotinib okanye i-gefitinib, kodwa nxamnye notshintsho olungaqhelekanga oluchasene nala machiza. Nangona kunjalo, ayisebenzi ngokuchasene notshintsho lwe-T790M olufuna ngokubanzi iziyobisi zesithathu ezifana ne-osimertinib Ngenxa yomsebenzi wayo owongezelelweyo ngokuchasene ne-Her2, kuphandwa ngomhlaza wamabele kunye nezinye i-EGFR kunye ne-Her2 yomhlaza oqhutywa.

 

Isicelo sePowderib Powder

I-Afatinib powder ifumene imvume yokulawula ukuba isetyenziswe njengonyango lomhlaza wamaphaphu ongaqhelekanga, nangona kukho ubungqina obuvelayo bokuxhasa ukusetyenziswa kwayo kweminye imihlaza efana nomhlaza webele.

 

Iziphumo zePowderib zePowder kunye nesilumkiso

Kuqheleke kakhulu (> 10% frequency)

▪ Urhudo (> 90%)

▪ Irash / dermatitis amabala asebusweni

▪ Isifo sesibindi

▪ IParonychia

▪ Ukunciphisa ukutya

▪ Impumlo yophe

▪ Ukurhawuzelela

▪ Isikhumba esomileyo

 

Ngesiqhelo (1-10% frequency)

▪ Ukuphelelwa ngamanzi emzimbeni, ukutshintsha incasa, iliso elomileyo

▪ ICystitis, Cheilitis, nefiva

▪ Ukubaleka / impumlo exineneyo

▪ Iqondo eliphantsi le potassium egazini

▪ Ukudumba ngokudibana

▪ Ukunyusa iALT

▪ Ukunyuka kwe-AST

▪ Isifo seenyawo zenyawo

▪ Ukudumba kwezihlunu

▪ Ukuphazamiseka kwezintso kunye / okanye ukusilela

 

Ngokungaqhelekanga (i-0.1-1% yokuhamba rhoqo)

▪ Isifo sokudumba komzimba

Isifo semiphunga

 

isingqiniso

[1] “IGilotrif (i-afatinib powder) ithebhulethi, umboniso bhanyabhanya”. Yonke imihla. I-Boehringer Ingelheim Pharmaceuticals, Inc. nge-18 ka-Okthobha ka-2019. Ifunyenwe nge-4 Novemba 2020.

[2] USpreitzer H (13 Meyi 2008). "Neue Wirkstoffe - Tovok". I-resterreichische Apothekerzeitung (ngesiJamani) (10/2008): 498

[3] UMinkovsky N, uBerezov A (uDisemba 2008). “IBIBW-2992, i-receptor ezimbini tyrosine kinase inhibitor kunyango lwamathumba aqinileyo”. Uluvo lwangoku lweziyobisi. 9 (12): 1336-46. IINKCUKACHA:

[4] “Afatinib Powder”. US Food and Drug Administration. 12 July 2013.[dead link] [5] “Giotrif Afatinib Powder (as afatinib dimaleate)” (PDF). TGA eBusiness Services. Boehringer Ingelheim Pty Limited. 7 November 2013. Retrieved 28 January 2014.

[6] IVavalà T (2017). "Indima ye-afatinib powder kunyango lwe-lung squamous cell carcinoma". Ikhemesti yezonyango. 9: 147-157. ikhonkco: 10.2147 / CPAA.S112715. I-PMID 5709991.


  • ICabozantinibfree Funda ngokugqithisileyo
  • Gefitinibfree Funda ngokugqithisileyo
  • I-AZD-9291free Funda ngokugqithisileyo